| Entry |
|
|---|
| Name |
|
|---|
| Formula |
C23H27ClO7
|
|---|
| Exact mass |
450.1445
|
|---|
| Mol weight |
450.9093
|
|---|
| Structure |
|
|---|
| Remark |
|
|---|
| Brite |
Glycosides [BR:br08021]
C-glycosides
C22194 Empagliflozin
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
A10BK03 Empagliflozin
D10459 Empagliflozin (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Agents
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhbitor
Empagliflozin
D10459 Empagliflozin (JAN/USAN/INN)
Cardiovascular Agents
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i)
Empagliflozin
D10459 Empagliflozin (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
219 Miscellaneous
2190 Miscellaneous
D10459 Empagliflozin (JAN/USAN/INN)
3 Agents affecting metabolism
39 Other agents affecting metabolism
396 Antidiabetic agents
3969 Others
D10459 Empagliflozin (JAN/USAN/INN)
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01794 SGLT2 inhibitor
D10459 Empagliflozin
Metabolizing enzyme substrate
DG02924 UGT substrate
DG03184 UGT1A3 substrate
D10459 Empagliflozin
DG03186 UGT1A8 substrate
D10459 Empagliflozin
DG03188 UGT1A9 substrate
D10459 Empagliflozin
DG03190 UGT2B7 substrate
D10459 Empagliflozin
Transporter substrate
DG01665 ABCB1 substrate
D10459 Empagliflozin
DG01913 ABCG2 substrate
D10459 Empagliflozin
Drug classes [BR:br08332]
Antidiabetic agent
DG01794 SGLT2 inhibitor
D10459 Empagliflozin
DG02044 Hypoglycemic agent
D10459 Empagliflozin
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC5
SLC5A2 (SGLT2)
D10459 Empagliflozin (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10459
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10459
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10459
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10459
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10459
Drug transporters
D10459
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 31
1 C8y C 15.1183 -17.5680
2 C8x C 15.1183 -18.9678
3 C8x C 16.3081 -19.6678
4 C8y C 17.5680 -18.9678
5 C8y C 17.5680 -17.5680
6 C8x C 16.3081 -16.8681
7 C1b C 18.7579 -16.8681
8 C8y C 20.0177 -17.5680
9 C8x C 20.0177 -18.9678
10 C8x C 21.2076 -19.6678
11 C8y C 22.3974 -18.9678
12 C8x C 22.3974 -17.5680
13 C8x C 21.2076 -16.8681
14 X Cl 18.7579 -19.6678
15 O2a O 23.5873 -19.6678
16 C1y C 24.7772 -18.9678
17 C1y C 13.9284 -16.8681
18 O2x O 13.9284 -15.4682
19 C1y C 12.6686 -14.7683
20 C1y C 11.4787 -15.4682
21 C1y C 11.4787 -16.8681
22 C1y C 12.6686 -17.5680
23 O1a O 12.6686 -18.9678
24 O1a O 10.2888 -14.7683
25 O1a O 10.2888 -17.5680
26 C1b C 12.6686 -13.3685
27 O1a O 13.9284 -12.6686
28 C1x C 26.1070 -19.5278
29 O2x O 27.0169 -18.4779
30 C1x C 26.3170 -17.2880
31 C1x C 24.9172 -17.5680
BOND 34
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 5 7 1
8 7 8 1
9 8 9 2
10 9 10 1
11 10 11 2
12 11 12 1
13 12 13 2
14 8 13 1
15 4 14 1
16 11 15 1
17 16 15 1 #Up
18 17 1 1 #Up
19 17 18 1
20 18 19 1
21 19 20 1
22 21 20 1
23 21 22 1
24 22 17 1
25 22 23 1 #Down
26 20 24 1 #Down
27 21 25 1 #Up
28 19 26 1 #Up
29 26 27 1
30 16 28 1
31 28 29 1
32 29 30 1
33 30 31 1
34 16 31 1
|
|---|
